NHS Trust Adds Doctors to Speed Up Breast Cancer Review

Published: 13 August 2026. The English Chronicle Desk. The English Chronicle Online

An NHS trust in County Durham has recruited additional specialist doctors to accelerate a major review into failures in its breast cancer services, after an investigation found that some patients underwent unnecessary surgery, experienced missed cancers and received care below expected standards.

County Durham and Darlington NHS Foundation Trust (CDDFT) is reviewing thousands of cases involving former breast cancer patients who received treatment at University Hospital of North Durham and Darlington Memorial Hospital.

The review follows serious concerns identified in an earlier report into the trust’s breast cancer services. The findings prompted the NHS organisation to examine whether patients had been harmed as a result of shortcomings in diagnosis, treatment and clinical decision-making.

So far, the trust has reviewed around 500 cases covering treatment provided between 2023 and February 2025.

Its findings have identified significant harm among some patients. The trust said one patient had died as a result of its failings, while 19 patients had experienced severe harm and 55 had suffered moderate harm.

The scale of the review means the process remains substantial.

Around 1,000 cases are still to be examined, leaving the trust with a considerable amount of work before it can establish the full extent of the problems within the service.

To accelerate the process, CDDFT has recruited three oncoplastic breast surgeons. Their arrival increases the number of doctors involved in reviewing cases to nine.

Oncoplastic breast surgery combines cancer surgery with reconstructive techniques and requires specialist expertise in both the treatment of breast cancer and the management of the physical consequences of surgery.

The trust said bringing in the additional specialists would help increase the pace at which cases can be examined and ensure that patients’ treatment histories receive appropriate clinical scrutiny.

The organisation is expected to provide a clearer indication of when the review will be completed in September.

The review has been taking place against the background of serious concerns about the quality and safety of the trust’s breast cancer services.

The earlier report found that unnecessary operations had been carried out and that some cancers had been missed. It also identified poor standards of care within the service.

Such failures can have profound consequences for patients because delays in diagnosing breast cancer can affect treatment options and outcomes.

For patients who have already undergone treatment, discovering that their care may have been affected by clinical failings can also create uncertainty about whether their diagnosis and treatment were appropriate.

The trust has therefore been attempting to establish which patients were affected and what level of harm may have occurred.

In a recent report, CDDFT said three of the 75 patients it had identified as having been harmed by treatment could not be contacted despite sustained efforts.

The trust’s continuing review is intended not only to identify patients who may have experienced harm but also to provide a clearer understanding of how the failures occurred.

That information could be important in determining what changes are required to prevent similar problems from happening again.

The trust is also facing continuing pressures within its breast cancer service.

Breast cancer waiting times remain “too high”, with patients currently waiting around six weeks on average, according to the organisation.

CDDFT attributed the delays to a combination of factors, including shortages of radiology staff and limitations in available equipment.

Radiology plays a central role in breast cancer diagnosis because imaging can help identify suspicious abnormalities and determine whether further investigation or treatment is necessary.

Shortages of specialist staff and equipment can therefore create significant pressure on services already dealing with high demand.

The trust said its immediate priority was to increase capacity and make the service more sustainable.

As part of that effort, the number of patients the service can treat each week is due to increase.

From September, the patient cap will rise from 90 patients per week to 100.

The planned increase is intended to provide greater capacity while the trust works to address the underlying problems affecting the service.

Despite the difficulties, the trust noted that the Northern Cancer Alliance had assessed its performance as being in line with, or better than, that of regional peers.

That assessment provides some context around the current performance of the service, although it does not remove the concerns raised by the earlier review.

The trust faces the difficult task of improving current services while simultaneously investigating historical failures.

For patients and their families, the review’s pace is likely to remain an important issue.

Every case requires individual examination of medical records and treatment decisions, meaning that a rapid review must still maintain sufficient clinical oversight to ensure that conclusions are accurate.

The recruitment of three additional oncoplastic breast surgeons suggests the trust has recognised the need for greater specialist capacity.

Increasing the review team from six to nine doctors could help distribute the workload and reduce the time required to assess the remaining cases.

However, with approximately 1,000 cases still outstanding, the process is unlikely to be completed immediately.

The trust’s decision to provide a clearer timetable in September may therefore be closely watched by patients, families and campaigners seeking answers about the failures.

The findings already identified raise questions about how the problems developed within the service and why they were not detected earlier.

The cases involving unnecessary surgery and missed cancers are particularly serious because they concern decisions at the centre of cancer diagnosis and treatment.

For healthcare organisations, reviewing such failures is also part of a broader process of clinical governance and patient safety.

A comprehensive review can help identify patterns that individual investigations might miss. By examining a large number of cases, clinicians can determine whether particular types of treatment, diagnostic decisions or operational problems contributed to patient harm.

The trust’s review may therefore have implications beyond the individual patients whose cases are being examined.

It could inform changes to staffing, clinical supervision, diagnostic processes, equipment provision and patient monitoring.

The continuing waiting-time pressures add another dimension to the challenge.

While the trust works through historic cases, it must also ensure that patients currently entering the breast cancer pathway receive timely investigations and treatment.

Increasing weekly capacity from 90 to 100 patients is one response, but the organisation has acknowledged that wider structural problems, including staffing and equipment shortages, need to be addressed.

The situation also illustrates some of the pressures facing specialist NHS services more broadly.

Breast cancer services depend on multidisciplinary teams involving surgeons, radiologists, pathologists, oncologists, nurses and other healthcare professionals.

A shortage in one part of that system can create delays elsewhere.

At the same time, rising demand and increasingly complex treatment requirements can place additional pressure on existing staff.

For patients who were treated during the period under review, however, the most immediate concern is whether their own care was affected.

The trust’s review is intended to answer that question on a case-by-case basis.

The finding that one patient died as a result of the trust’s failings underscores the seriousness of the investigation. The identification of 19 cases involving severe harm and 55 involving moderate harm also demonstrates that the consequences have extended beyond administrative or procedural shortcomings.

The trust will now need to balance the urgency of completing the review with the need to provide patients with reliable answers.

It will also need to demonstrate that lessons identified through the process are translated into concrete improvements.

The recruitment of additional specialists represents one step in that direction.

As the review continues, patients and their families will be looking for transparency about the remaining cases, the causes of the failures and the measures being introduced to improve safety.

The trust’s promise of a clearer completion timetable in September could provide greater certainty about the next stage.

For now, the review remains a major undertaking, with around 1,000 cases still awaiting assessment.

At the same time, CDDFT is attempting to reduce current waiting times, increase capacity and strengthen the long-term sustainability of its breast cancer services.

The ultimate measure of the response will not simply be how quickly the review is completed, but whether the findings lead to lasting improvements in patient safety and confidence.

For the patients affected by the failures, the process represents an opportunity to establish what went wrong and ensure that similar problems are not repeated.

Checkout Our Latest News On>>